GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Inventories, Finished Goods

3D Medicines (HKSE:01244) Inventories, Finished Goods : HK$0.0 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines Inventories, Finished Goods?

3D Medicines Inventories, Finished Goods Historical Data

The historical data trend for 3D Medicines's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3D Medicines Inventories, Finished Goods Chart

3D Medicines Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Inventories, Finished Goods
- - - -

3D Medicines Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Inventories, Finished Goods Get a 7-Day Free Trial - - - - -

3D Medicines Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

3D Medicines (HKSE:01244) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » Inventories, Finished Goods
Comparable Companies
HKSE:02616 HKSE:01873 HKSE:06622 HKSE:01167 HKSE:06978 HKSE:02496 HKSE:01672 HKSE:02181 HKSE:02256 HKSE:02137 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN
Website
https://www.3d-medicines.com
3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.
Executives
Gong Zhaolong 2101 Beneficial owner
Zhu Pai 2101 Beneficial owner
Dragon Prosper Holdings Limited 2101 Beneficial owner
Simcere Pharmaceutical Group Limited 2101 Beneficial owner
Gong Zhaolong 2501 Other
Immunal Medixin Us Limited 2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership) 2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd. 2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.) 2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership) 2201 Interest of corporation controlled by you
Zhu Jinqiao 2103 Interests held jointly with another person

3D Medicines (HKSE:01244) Headlines

No Headlines